Transformative Neuropsychiatric Therapies ft. Dr. Amit Etkin, Founder, President and CEO of Alto Neuroscience

In this episode, Ayesha spoke with Amit Etkin, Founder, President and CEO of Alto Neuroscience, a company developing precision treatments for neuropsychiatric conditions.

Alto Neuroscience is focused on designing candidates that target core brain processes in patient populations not adequately treated by currently available medications. Alto is currently pursuing candidates in major depressive disorder (MDD), bipolar depression and schizophrenia.

Mental health disorders are a leading cause of disability globally. In the US alone, 1 in 5 people are living with a mental health disorder, with an estimated $280 billion spent on mental health services in the country in 2020. Despite significant need, the current standard of care consists of treatments that are ineffective for many patients.

Dr. Amit Etkin founded Alto in 2019 and is the president, CEO and serves as chair of the company’s board of directors. Prior to founding Alto, Dr. Etkin was a tenured professor of psychiatry and behavioral sciences at Stanford University, where he held multiple leading roles.

His research contributions during his tenure at Stanford led to Dr. Etkin being awarded the National Institutes of Health (NIH) Director’s Pioneer Award, the most competitive and prestigious NIH grant, and the first in history to be awarded in clinical psychiatry. He also received an Entrepreneur of the Year (EY) award.

Tune into the episode to hear from Dr. Etkin about innovations in treatments for neuropsychiatric disorders at Alto Neuroscience.

For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/

Follow Us on Social Media

Twitter: https://twitter.com/Xtalks
Instagram: https://www.instagram.com/xtalks/
Facebook: https://www.facebook.com/Xtalks.Webinars/
LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
YouTube: https://www.youtube.com/c/XtalksWebinars/featured